传染病治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00016883
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 193
Buy Now

【研究报告】2022年传染病治疗市场规模为11970877万美元,预计到2030年将达到16788393万美元;预计 2022 年至 2030 年市场复合年增长率为 4.30%。
市场洞察和分析师观点:
传染病治疗市场预测可以帮助该市场的利益相关者规划其增长战略。
传染病可以通过直接或间接接触从一个人传播给另一个人。患者必须服用具有抗感染特性的药物才能治疗传染病。细菌、真菌、病毒和寄生虫等病原体是这些疾病的主要原因。为了针对引起疾病的生物体并实施治疗,直接针对宿主的防御系统。
生长驱动力:
传染病是由病毒、寄生虫、细菌、真菌、有毒产物和其他传染性物质引起的代理。艾滋病毒是全世界的一个重大公共卫生问题。根据联合国艾滋病毒/艾滋病联合规划署 (UNAIDS) 的数据,2020 年,约有 3770 万人感染艾滋病毒。其中,3600 万人是成年人,170 万人是 0-14 岁的儿童。此外,超过一半(53%)是女孩和妇女。此外,2020 年全球报告了 150 万新的艾滋病毒病例。同样,肝炎是由病毒感染引起的肝脏感染。肝炎病毒的主要类型为甲型、乙型、丙型、丁型和戊型。据世界卫生组织 (WHO) 统计,全球约有 5800 万人患有慢性丙型肝炎病毒感染,每年约有 150 万人患有慢性丙型肝炎病毒感染。出现新的感染。
根据世界卫生组织的数据,结核病 (TB) 是全球第 13 大死亡原因,也是仅次于 COVID-19 的第二大传染病。 2020 年,结核病导致 150 万人死亡(其中 214,000 人感染艾滋病毒)。此外,2020年全球有1000万人患有结核病,其中包括110万儿童、330万女性和560万男性。此外,医院获得性感染或医疗保健相关感染(HAI)的发病率和死亡率很高。此外,每年医疗保健系统的支出也是巨大的。美国疾病控制与预防中心 (CDC) 报告称,医院感染每年在美国医院造成约 170 万例感染病例和 99,000 例死亡。因此,全球传染病流行率的上升可能会推动传染病治疗市场规模的增长。
战略见解
报告细分和范围:
传染病治疗市场预测涉及根据药物类别、适应症、给药途径和分销渠道进行市场细分。传染病治疗市场按药物类别细分为抗病毒、抗菌、抗真菌等。此外,抗病毒药物领域在 2022 年占据最大的市场份额;预计抗菌领域在预测期内将达到市场上最高的复合年增长率。根据适应症,传染病治疗市场分为艾滋病毒、肝炎、结核病、流感、HPV 等。 HIV 细分市场在 2022 年占据最大的市场份额,预计 2022 年至 2030 年复合年增长率最高。就给药途径而言,传染病治疗市场分为口服、肠胃外、外用等。口腔细分市场在 2022 年占据最大的市场份额,预计 2022 年至 2030 年复合年增长率最高。传染病治疗市场按分销渠道分为医院药房、零售药房等。医院药房细分市场在 2022 年占据最大的市场份额,预计 2022 年至 2030 年复合年增长率最高。
细分分析:
按药物类别划分,传染病治疗市场分为抗病毒药物、抗病毒药物和抗病毒药物。 -细菌、抗真菌等。 2022年,抗病毒药物占据最大市场份额;预计 2022 年至 2030 年抗菌领域的复合年增长率最高。
抗病毒药物是经美国食品和药物管理局 (FDA) 批准用于治疗病毒感染的药物。抗病毒药物通常针对病毒生命周期的不同阶段。抗病毒药物可用于预防、治疗和抑制明显的疾病。多种策略用于开发抗病毒药物,包括针对酶、病毒蛋白或核酸的直接作用抗病毒药物;被动抗体中和循环病毒;以及针对病毒复制必需的细胞蛋白或过程的药物。目前提供的抗病毒药物中有一半用于治疗人类免疫缺陷病毒(HIV)感染。其他药物主要用于治疗疱疹病毒、乙型肝炎、丙型肝炎和呼吸道病毒。例如,根据世界卫生组织的统计,2019年,全球有69万人死于艾滋病毒,新增艾滋病毒感染病例170万例,总病例数约3800万例。因此,上述因素可能有利于传染病治疗市场的增长。
传染病治疗市场,按药物类别 - 2022 年和 2030 年
根据适应症,传染病治疗市场分为 HIV、肝炎、结核病、流感、HPV 等。 HIV 细分市场在 2022 年占据最大市场份额,预计 2022 年至 2030 年市场复合年增长率最高。艾滋病毒通过破坏抵抗疾病和感染的重要细胞来削弱个体的免疫系统。由于各种因素,包括性伴侣和危险行为,美国的某些人群比其他人群更容易感染艾滋病毒。由于艾滋病毒对免疫系统的抑制作用不断增强,手术后感染的风险可能会上升。近年来,艾滋病病毒感染者人数持续上升。自从引入抗逆转录病毒疗法(ART)以来,艾滋病毒感染者和艾滋病患者的预期寿命显着增加。因此,随着手术护理需求的不断增加以及艾滋病毒感染引起的手术疾病的流行,预计传染病治疗市场在预测期内将会增长。
传染病治疗市场分析,由给药途径已考虑以下部分进行:口服、肠胃外、局部和其他。口服药物在 2022 年占据最大的市场份额,预计 2022-2030 年将在传染病治疗市场中实现最高的复合年增长率。根据美国国立卫生研究院的报告,口服抗感染药物是一种方便、经济且最常用的患者给药途径。此外,抗感染药物的口服给药途径比肠胃外/静脉注射途径更常见。例如,与口服途径相关的主要优点包括不存在插管相关感染或血栓性静脉炎、药物成本低以及减少隐性成本,例如减少对卫生专业人员和静脉注射抗感染药物的设备的需求。 Frontiers SA 报告指出,约 60% 的商业化抗感染产品是口服给药。此外,口服抗感染制剂约占全球患者用药制剂市场份额的 90%。
按分销渠道,传染病治疗市场分为医院药房、零售药房等。 2022 年,就收入而言,医院药房在全球传染病治疗市场份额中占据主导地位。
医院药房致力于持续维护和改进药物管理,使其达到医院环境中的最高标准。医院药房是医院储存、采购、配制、配发和分发各种药品的主要区域之一。监督医院和医疗机构药品的使用是医院药房的主要职责之一。药品的选择、采购、交付、管理和审查是医院药房旨在改善患者治疗效果的目标之一。
区域分析:
从地理上看,全球传染病治疗市场分为北美、欧洲、亚太地区、南美洲和中美洲以及中东和非洲。 2022年,就收入而言,北美主导全球传染病治疗市场份额。对治疗传染病的先进治疗解决方案的需求不断增长以及研发活动的不断增加等因素推动了该地区传染病治疗市场的增长。
亚太地区预计 2022-2030 年复合年增长率最高。由于全球医疗保健支出不断增加、慢性病和传染病发病率增加以及老年人口基数不断增长,该地区的传染病治疗市场预计将增长。流感、乙型肝炎、感染性腹泻等传染病在中国很常见,而印度则有伤寒、疟疾、黄疸、肺结核、艾滋病等高发疾病。
行业发展及未来机遇:
传染病发病率的上升预计将增加发展中国家传染病治疗药物的销售。由于数据需求适度减少和严格的法规,亚太地区已成为一个适应性强且有利于商业的中心。此外,新兴国家对健康研究和生命科学的高投入对于促进发展中国家的最新技术发挥着关键作用,这反过来又支持了传染病诊断和治疗的倾向。例如,联合国艾滋病规划署主张到2025年投资290亿美元,以满足中低收入国家预防和治疗艾滋病的需求。印度、韩国、巴西、墨西哥等地肝炎、HAI、HIV、流感等传染病高发;大量患者;人口可支配收入增加;改善医疗保健基础设施;以及日益增长的医疗旅游业。因此,这些国家新兴传染病治疗市场中的关键传染病治疗产品制造商预计将在未来见证利润丰厚的机会。
竞争格局和主要公司:
辉瑞公司、吉利德科学公司、F. Hoffmann- La Roche Ltd、Shionogi & Co Ltd、Bayer AG、BioCryst Pharmaceuticals Inc、GSK Plc、AbbVie Inc、Merck & Co Inc 和 Astellas Pharma Inc 是传染病治疗市场报告中介绍的主要参与者。这些公司专注于新技术、升级现有产品和地域扩张,以满足全球不断增长的消费者需求。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Which distribution channel segment is dominating the infectious disease therapeutics market?

The infectious disease therapeutics market, based on distribution channel, segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest share of the market in 2022 and is anticipated to register highest CAGR during 2022–2030.

Which region is the fastest growing the infectious disease therapeutics market?

Asia Pacific is expected to be the fastest growing region in the infectious disease therapeutics market. The projected growth of the market in the coming years is attributed to rising global healthcare expenditure, increasing incidence of chronic and infectious diseases, and a growing geriatric population base.

Which route of administration segment is dominating the infectious disease therapeutics market?

The infectious disease therapeutics market, based on route of administration, categorized into oral, parenteral, topical, and others. The oral segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market during 2022-2030.

Which indication segment is dominating the infectious disease therapeutics market?

The infectious disease therapeutics market, based on indications, is bifurcated into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market during 2022–2030.

Which drug class segment is dominating the infectious disease therapeutics market?

The infectious disease therapeutics market, based on drug class, is segmented into anti-viral, anti-bacterial, anti-fungal, and others. In 2022, the anti-viral segment held the largest share of the market. However, the anti-bacterial segment is expected to record the highest CAGR during 2022-2030.

Which country is dominated the infectious disease therapeutics market?

US holds the largest market share in infectious disease therapeutics market. The burgeoning demand for antiviral agents due to the growing adoption of antiviral therapies is anticipated to drive the market in the US.

Who are the major players in the infectious disease therapeutics market?

The infectious disease therapeutics market majorly consists of the players such as Pfizer Inc, Gilead Sciences Inc, F. Hoffmann-La Roche Ltd, Shionogi & Co Ltd, Bayer AG, BioCryst Pharmaceuticals Inc, GSK Plc, AbbVie Inc, Merck & Co Inc, and Astellas Pharma Inc among others.

What are the driving factors for the infectious disease therapeutics market across the globe?

The factors that are driving growth of the market are rising prevalence of infectious disease and rising prevalence of infectious disease.

What is infectious disease therapeutics?

Infectious diseases can transfer from one person to another through direct or indirect contact. Patients must take medications with anti-infective properties in order to treat infectious diseases. Pathogens such as bacteria, fungi, viruses, and parasites are the primary cause of these disorders. In order to target the organism causing the sickness and implement a remedy, the host's defensive system is directly targeted. A huge geriatric population has presented a significant opportunity for the market for infectious disease therapeutics to grow in the coming years.

The List of Companies - Infectious Disease Therapeutics Market

  1. Pfizer Inc
  2. Gilead Sciences Inc
  3. F. Hoffmann-La Roche Ltd
  4. Shionogi & Co Ltd
  5. Bayer AG
  6. BioCryst Pharmaceuticals Inc
  7. GSK Plc
  8. AbbVie Inc
  9. Merck & Co Inc
  10. Astellas Pharma Inc

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports